Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2313 in Relapsed/Refractory Hematological Malignancies
NCT07294300Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS2313 in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 2 years, Maximum Tolerated Dose at 2 years and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QLS2313
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07294300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294300.